Phase 2 Crohn's Disease and Colitis Trial, Recruiting NCT07501078 Sponsor: Muhammad N Aslam, MD Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 2 Crohn's Disease and Colitis Trial, Recruiting

NCT07501078
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be able to read and sign a consent form agreeing to take part (or, if appropriate, give your agreement in another acceptable way).
  • You must have ulcerative colitis (a type of bowel disease) and have had a specific surgery called a J-pouch procedure — where part of your bowel was reshaped into a pouch connected to your anal passage — within the last eight months, and you must no longer have a stoma bag (ileostomy).
  • If you are a woman aged 11 or older who has not yet gone through menopause and still has your reproductive organs, you must have a negative pregnancy test within two weeks before your first study visit, and you must agree to use an acceptable form of birth control throughout the study.

Who may not be able to join:

  • Women who are pregnant or currently breastfeeding, or women who could become pregnant but are not willing to use acceptable birth control during the study, cannot take part.
  • You cannot currently be taking part in another clinical trial that uses an experimental drug or treatment.
  • People who are unlikely to be able to follow the study's instructions or attend required appointments cannot take part.
  • You cannot join if you have ever been diagnosed with Crohn's disease (another type of bowel disease).
  • You cannot join if you have a history of certain inherited bowel conditions, serious bowel bleeding or complications, or tumors that cause excess stomach acid (confirm with trial site).
  • You cannot join if you have ever been diagnosed with any cancer of the digestive system.
  • You cannot join if you have kidney disease, kidney stones, high calcium levels in your blood, or if you have had sudden kidney failure in the last 12 weeks. (Note: if you may have passed a kidney stone more than three years ago but have had no problems since, this may not exclude you — confirm with trial site.)
  • You cannot join if you have a hereditary blood clotting disorder or a condition that causes abnormal bleeding, or if you are currently taking high doses of blood-thinning medicines such as warfarin or heparin.
  • You cannot join if you have used any of the following in the past 30 days, or are unwilling to stop using them for 30 days before starting the study:
    • Calcium or magnesium supplements, including most multivitamins that contain these minerals or fiber supplements. (Multivitamins that contain no minerals at all are allowed.)
    • Anti-inflammatory painkillers such as ibuprofen or naproxen, except for occasional pain relief or low-dose aspirin taken to protect your heart.
    • Steroid tablets or rectal steroid treatments (such as prednisone) or antibiotic medicines — though these may be allowed briefly if your own doctor prescribes them during a flare-up after you have already joined the study. Steroid inhalers or steroid creams applied to the skin are allowed and will not exclude you.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Muhammad N Aslam, MBBS, MD, University of Michigan

Phone: 734-615-7236

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Muhammad N Aslam, MD
Registry
ClinicalTrials.gov
Start date
1 July 2026
Est. completion
1 May 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Time to clinical onset of pouchitis using the Modified Pouchitis Disease Activity Index (mPDAI) clinical symptoms section

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov